Equities

Farmacias Benavides SAB de CV

Farmacias Benavides SAB de CV

Actions
  • Price (USD)0.75
  • Today's Change0.00 / 0.00%
  • Shares traded974.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 18 2024 17:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of MXN
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments700636495
Total Receivables, Net895497480
Total Inventory3,2002,7262,440
Prepaid expenses--5563
Other current assets, total01616
Total current assets4,7963,9313,495
Property, plant & equipment, net3,2793,1692,880
Goodwill, net------
Intangibles, net445359
Long term investments------
Note receivable - long term------
Other long term assets827378
Total assets8,7397,7256,882
LIABILITIES
Accounts payable3,9013,2522,806
Accrued expenses------
Notes payable/short-term debt--00
Current portion long-term debt/capital leases547544540
Other current liabilities, total830893720
Total current liabilities5,2784,6894,066
Total long term debt1,8571,6561,352
Total debt2,4042,2011,893
Deferred income tax------
Minority interest------
Other liabilities, total1,2581,1991,504
Total liabilities8,3927,5446,923
SHAREHOLDERS EQUITY
Common stock733733733
Additional paid-in capital------
Retained earnings (accumulated deficit)(299)(511)(698)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(86)(40)(75)
Total equity347182(41)
Total liabilities & shareholders' equity8,7397,7256,882
Total common shares outstanding409409409
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.